BACKGROUND: Diverticular disease of the colon is a common disorder, characterized by recurrent symptoms and complications such as diverticulitis, requiring hospital admissions and surgery.
D iverticular disease (DD) of the colon accounts for an impressive clinical burden in Europe and the United States, in terms both of outpatient and inpatient care. 1 Diverticula in the colon are asymptomatic in most cases (ie, colonic diverticulosis) and the prevalence increases with age from 10% in patients Ͻ40 years old to Ͼ60% in patients Ͼ80 years. 2, 3 Only approximately 20% of affected individuals develop symptomatic DD, including abdominal pain or discomfort, bloating, and changes in bowel habits. Whether some patients presenting DD of the colon have symptoms with similar underlying pathogenetic mechanisms to those with irritable bowel syndrome is still a matter of debate, which, however, implies potential therapeutic implications. Complicated DD may be characterized by diverticulitis (ie, inflammation of one or more diverticula), invariably associated with gross or microscopic perforation. 4 Treatment of DD, aimed at relieving symptoms and/or preventing major complications, is suggested mainly for patients with recurrent uncomplicated DD. 5 The standard therapeutic approach of symptomatic colonic DD still remains to be defined. A high-dose fiber diet or treatment with nonabsorbable antibiotics, mesalazine, and probiotics, either alone or in combination, has been used. 6 However, although many reviews and practice guidelines for the treatment of DD have been published, the quality of clinical studies and the evaluation of the efficacy of therapy on symptoms and prevention of acute diverticulitis, in relation to the clinical features of the patients, have not been considered so far.
In this systematic review, we assessed the quality of the prospective trials appearing in the literature and the efficacy of the treatment approaches, including fiber supplementation, antibiotics, mesalazine, probiotics, and antispasmodics, for patients with uncomplicated colonic DD, to improve symptoms, maintain remission of symptoms, and prevent attacks of acute diverticulitis.
METHODS Data Sources and Selection
To select the studies included in this review, we made a search of MEDLINE and Embase, referring to the period 1966 to February 2010. The search strategy covered issues related to DD or diverticulosis of the colon and treatment with dietary fiber, rifaximin, antibiotics, mesalazine, probiotics, or antispasmodics to improve symptoms, maintain remission of symptoms, and prevent acute diverticulitis. The detailed search strategy is as follows:
• Explore colonic disease with an additional search using key words: ((diverticulosis OR diverticular OR diver-ticula OR diverticulitis) AND (colon OR colonic OR sigmoid)) OR "diverticulosis, colonic" (MeSH) to assess all articles on colonic diverticulosis and DD of the colon • Combine with text words (Mesalamine OR mesalazine OR 5-ASA OR sulfasalazine OR balsalazide) OR "sulfasalazine" (MeSH) OR "mesalamine" (MeSH) • Combine with text words (Rifaximin OR Rifamycins OR #Tetracycline OR #Quinolones OR #Nitroimidazoles OR #beta-lactams OR #cephalosporins OR antibiotic*) OR "Rifamycins" (MeSH) OR "Tetracycline" (MeSH) OR "Quinolones" (MeSH) OR "Nitroimidazoles" (MeSH) OR "beta-lactams" (MeSH) OR "cephalosporins" (MeSH) • Combine with text words: (probiotic* OR prebiotic* OR lactobacilli OR bifidobacteria OR Escherichia OR VSL) OR "Probiotics" (MeSH) • Combine with text words ("dietary fiber" OR "dietary fibers" OR "bulking agent" OR "bulking agents" OR bran OR psyllium OR roughage* OR vegetables OR husk OR ispaghula OR sterculia) OR "Dietary fiber" (MeSH) • Combine with text words: (antispasmodic* OR bromide OR "peppermint oil" OR "mentha piperita" OR antispasmodic OR mebeverine OR trimebutine) OR "mebeverine" (Substance Name) OR "Trimebutine" (MeSH) OR "Parasympatholytics" (MeSH) OR "Butylscopolammonium Bromide" (MeSH) OR "Mentha piperita" (MeSH)
The following filter was used: NOT (Animal(MeSH) NOT (Human(MeSH) AND Animal(MeSH)).
In addition, manual searches of reference lists from potentially relevant articles and reviews were made to identify additional studies that may have been missed by using the computer-assisted search strategy.
This review included the following: 1) studies dealing with: a) symptomatic patients with DD of the colon without previous attacks of acute diverticulitis or no mention of this condition in their clinical history, or with one or more attacks of acute diverticulitis in the past year, and b) asymptomatic (previously symptomatic) patients, enrolled after a course of medical therapy with antibiotics, probiotics, or mesalazine for a recent (Ͻ3 mo) attack of acute diverticulitis or recurrent symptomatic DD of the colon. 2) Prospective open or randomized trials on uncomplicated DD of the colon, published as full articles, without specific language restriction or length of followup, with one or more of the following outcome measures: a) improvement in symptoms (percentage of subjects with reduction of symptoms), b) complete remission of symptoms at the end of follow-up (percentage of asymptomatic patients), and c) prevention of acute diverticulitis during DISEASES OF THE COLON & RECTUM VOLUME 54: 10 (2011) the follow-up (percentage of patients experiencing acute diverticulitis).
We excluded retrospective studies and articles addressing the treatment of acute diverticulitis or diverticular hemorrhage, segmental colitis associated with diverticulosis, or end points other than clinical outcome of DD of the colon.
Data Extraction and Assessment of the Methodological Quality of Individual Studies
All titles and/or abstracts identified by the electronic searches were independently scrutinized by 2 researchers. The reviewers checked whether inclusion and exclusion criteria were met and, in the event of uncertainty, the full text of articles was retrieved and reviewed, and eventual disagreement was resolved by consensus.
Assessment of the methodological quality of articles was made independently by 4 reviewers (M.G., G.B., R.C., B.A.). Data were extracted by more than one reviewer. Discordance was discussed between the reviewers and, in the case of disagreement, by the whole team.
Criteria for evaluating the quality of articles were derived from "Klein Criteria" for irritable bowel syndrome trials, 7 reevaluated according to Spiller. 8 These criteria were used in the present study rather than Consort statements, because most retrieved studies were planned or performed before the publication of this material, and because "Klein Criteria" (including almost all Consort statements) are designed to evaluate trials on clinical conditions with symptoms comparable to those of DD of the colon.
In brief, the criteria used were as follows ( Table 1) : 1) adequate patient definition. This should include assessment of colonic diverticulosis, description of clinical history, and patient symptoms 40 ; 2) statement of specific measures of efficacy and of adequate specific end points; 3) placebo control; 4) adequate length (Ն8 wk) of the study; 5) adequate study design; 6) adequate baseline comparison; 7) side-effects recorded and described; 8) dropouts Ͻ15%; and 9) appropriate statistics and sample size.
The following data were extracted where available: a) study design, b) number of patients enrolled, c) kind of interventions, d) treatment period, e) outcome measures, f) number and percentage of patients with improvement of symptoms after therapy, g) number and percentage of patients with no symptoms at the end of follow-up, h) number and percentage of patients who had acute diverticulitis, and i) number and percentage of patients who had side effects.
Data Synthesis and Analysis
The studies showed a wide heterogeneity in terms of type and clinical history of patients enrolled, trial end points, type of treatment and protocols, and length of follow-up, as well. A meta-analysis of each type of therapy was therefore hampered by the heterogeneity of the design of the studies and therapeutic schemes, by different trial end points, and, in particular, by multiple comparisons and the combination of drugs in most trials.
The results of the studies were summarized according to the major outcome (ie, improvement or remission of symptoms or prevention of acute diverticulitis) and the patient conditions (ie, symptomatic uncomplicated DD or asymptomatic uncomplicated DD).
RESULTS

Identification of Studies
A total of 1599 articles were initially identified, and a hand search of the reference lists of potentially relevant articles and pertinent reviews identified an additional 10 studies.
After removing nonpertinent articles (n ϭ 717) and duplicates (n ϭ 278), 614 full texts of potentially relevant studies were retrieved. Of these, 583 were excluded for various reasons (367 reviews, comments, letters, guidelines, editorials, and case reports; 18 therapeutic retrospective studies; 76 prospective epidemiological, clinical and experimental-not therapeutic-studies; 122 studies on acute or complicated diverticulitis or segmental diverticulitis), leaving 31 clinical trials. The remaining clinical trials included 24 prospective studies (4 with a crossover design and 20 with a parallel-group design) 9 -32 and 7 prospective noncomparative studies (not further described in the text). [33] [34] [35] [36] [37] [38] [39] 
Methodological Quality of Studies
According to the criteria of Klein and Spiller, only one trial 18 provided adequate information and satisfied almost all criteria. Furthermore, only 6 studies 9, 12, 14, 15, 18, 31 were "placebo-controlled" and 4 studies 9,12,14,18 fulfilled the "parallel group and double-blind" criteria. None of the studies provided complete information to satisfy the criteria for "adequate patient-selection and definition" (Table 1). In particular, only 10 trials provided a detailed description of the clinical patient history. Even if no study reported the number of patients with a history of acute diverticulitis and used computed tomography or ultrasound to select or exclude patients for enrollment, as well as to assess the outcome, namely the onset of acute diverticulitis, 8 studies appropriately assessed symptoms by the use of a validated and referenced questionnaire, and 14 studies defined patient inclusion and exclusion criteria correctly, including the assessment of concomitant diseases and therapeutic approaches.
Patients and Therapeutic Approach
Twenty-seven trials considered symptomatic patients with uncomplicated DD. 9 -23,25-28,31,33,35-39 Six of these trials included symptomatic patients with previous attacks of acute diverticulitis 19 -22,35,37 (Table 2 ). Four trials considered asymptomatic, but previously symptomatic patients, with uncomplicated disease, and one of these four trials included patients who had previously had previous acute diverticulitis. 24, 29, 30, 32 Improvement or Remission of Symptoms. Symptomatic Uncomplicated Diverticular Disease. The improvement or remission of symptoms in symptomatic uncomplicated DD was evaluated in 21 trials, including 7 randomized double-blind trials, 9, 10, 12, 14, 15, 18, 31 8 open randomized trials, 11, 16, 17, [21] [22] [23] [25] [26] [27] [28] and 6 open nonrandomized trials 13, 19, 20, [33] [34] [35] [36] [37] [38] [39] (Table 2) .
Randomized, double-blind trials: Six placebo-controlled studies investigated the effect of fiber supplementation and the combination of fiber plus rifaximin on the improvement of symptoms in a short-term (2-16 wk) and 1-year follow-up (one study). 9, 12, 14, 15, 18, 31 The short-course fiber supplementation (8 -16 wk of methylcellulose, dried psyllium husk, or bran) showed an overall clinical advantage in comparison with placebo in 3 small studies, 9, 12, 14 and a benefit in relieving constipation, but not lower bowel symptoms (comprising stool consistency, straining, incomplete emptying sensation, and flatus), pain, and a symptomatic general score (including nausea, vomiting, dyspepsia, abdominal distension, and flatulence), in a larger crossover study. 15 Two studies compared fiber supplementation, plus rifaximin (400 mg twice a day) or placebo, showing that symptoms such as abdominal pain and bloating were significantly improved by antibiotics, both over a long 18 and a short follow-up period. 31 In particular, the larger study including 168 patients showed that 69% of patients treated with fiber and rifaximin were symptomfree compared with 39.5% of patients treated with fiber and placebo at the end of 1-year follow-up (P Ͻ .005). 18 Another small double-blind trial (not placebo-controlled), compared a 4-week course of fiber plus antispasmodics (alverine citrate) vs the fiber sterculia (10 g daily) alone, and reported that alverine citrate showed some benefit in relieving the passage of blood and mucus, diarrhea, flatus, flatulence, and abdominal distension. 10 Open randomized trials: A crossover trial compared high roughage with bran supplementation or with antispasmodic plus the vegetable gum sterculia, over a 1-month follow-up period, and showed an improvement in pain, bowel habit, and distension with each treatment. 11 However, bran alone provided the best results in terms of the percentage of patients free of symptoms at the end of follow-up. Another trial prospectively randomly assigned 43 patients to receive high-fiber diet (30 -40 g daily) or lactulose (15 mL twice a day) for 12 weeks. 16 Both treatments were equally effective in improving bowel frequency and stool consistency, although some differences in favor of lactulose emerged as far as concerns regarding pain on bowel movement and abdominal pain. Three long-term trials compared rifaximin (400 mg twice a day for 1 wk/mo) plus glucomannan (2-4 g/d) or fiber supplementation (at least 20 g/d) vs glucomannan or fiber supplementation alone, showing a significant improvement in symptoms in patients treated with rifaximin. 17, 25, 26 The largest of these trials showed that 56.5% of patients were symptom-free after 1 year of follow-up in comparison with 29.2% of patients treated with fiber supplementation alone (P Ͻ .001). 25 Three studies by the same group (one is the continuation of the other) compared different doses of rifaximin (200 mg twice a day and 400 mg twice a day) and mesalazine (400 mg twice a day and 800 mg twice a day), showing that high-dose mesalazine was significantly more effective than rifaximin in obtaining the relief of symptoms, as assessed at 3, 6, and 12 months. 23, 27, 28 Another study, including patients with at least 2 attacks of acute diverticulitis in the previous year, comparing a 1-week/month course of mesalazine 800 mg twice a day associated with rifaximin 400 mg twice a day vs rifaximin alone, showed a significant improvement in symptoms and a significantly higher rate of symptom-free patients at the end of 1-year follow-up (85.6% vs 49.4%) with combination therapy. 21 Asymptomatic-Previously Symptomatic-Uncomplicated Diverticular Disease. Four open long-term randomized trials by Tursi at al, 24, 29, 30, 32 including a total of 235 patients, assessed the maintenance of symptom-free remission in asymptomatic patients with previously symptomatic DD. These studies compared intermittent (10 d/mo) vs continuous administration of mesalazine or balsalazide, alone or together with probiotics (Lactobacillus casei or VSL#3), and probiotics alone over 12-to 24-month periods, showing an overall benefit of the combination therapies with the absence of symptoms at 12 months in 67 of 74 (90.5%) patients treated with mesalazine or balsalazide plus probiotics, 79 of 93 (84.9%) patients treated with mesalazine, and 51 of 68 (75%) patients treated with probiotics alone.
Prevention of Acute Diverticulitis. Symptomatic Uncomplicated Diverticular Disease.
Randomized, double-blind, placebo-controlled trials: Only one double-blind, placebo-controlled trial was found that assessed the prevention of acute diverticulitis. This was a 1-year follow-up trial in which all patients received glucomannan (2 g/d); one arm was administered rifaximin (400 mg twice a day for 7 days each month), and the other arm received a placebo. The results showed that both regimens were equally effective in preventing acute diverticulitis, which occurred in 2.4% of patients in both study arms 18 (Table 3) .
Open randomized trials: Data from 3 open randomized trials (comprising a total of 1492 patients), 17, 25, 26 comparing rifaximin plus glucomannan or fiber supplementation DISEASES OF THE COLON & RECTUM VOLUME 54: 10 (2011) vs glucomannan or fiber alone, reported that rifaximin led to a slight benefit in preventing acute diverticulitis, but only the largest study showed slightly significant results 25 (Table 3 ). However, cumulative data from placebo-controlled 18 and unblinded trials 17, 25, 26 showed that the rate of acute diverticulitis was significantly less frequent in patients treated with rifaximin plus fiber supplementation than with fiber alone (11/970 (1.1%) vs 20/690 (2.9%); P ϭ .012). However, according to these results, the number needed to be treated to prevent an attack of acute diverticulitis in 1 year with the rifaximin plus fiber supplementation regimen reached 57.
Another long-term study showed a nonsignificant benefit of pulsed mesalazine vs pulsed rifaximin treatment in preventing acute diverticulitis. 27 In symptomatic patients with a history of recent attacks of acute diverticulitis, 2 open randomized trials showed that acute diverticulitis was significantly reduced with the use of mesalazine (800 mg twice a day 1 wk/mo) plus rifaximin (400 mg twice a day 1 wk/mo) compared with rifaximin alone (400 mg twice a day 1 wk/mo) (2.8% vs 18%; P Ͻ .001) and with probiotics compared with no treatment. 21, 22 It is worthwhile pointing out that the 1-year prevalence of diverticulitis, observed with rifaximin in one of these studies (18%), is higher than that reported in previous randomized trials (1.1%), suggesting that the occur-rence of this complication may be affected by features of the patients.
Asymptomatic-Previously Symptomatic-Uncomplicated Diverticular Disease. Four randomized open trials by
Tursi et al, 24, 29, 30, 32 which compared mesalazine, balsalazide, alone or in combination with probiotics, and probiotics alone in preventing acute diverticulitis, did not show a significant difference among treatments; they reported 7 episodes of acute diverticulitis in more than 350 patients per year (yearly incidence rate, 2%).
Evaluation of Side Effects.
Only one long-term, doubleblind, placebo-controlled study evaluated the rate of side effects; this study reported the absence of side effects both for fiber alone and for fiber plus rifaximin. In other comparative studies, the rate of side effects with either fiber, probiotics, rifaximin, mesalazine, or their combination was lower than 5% ( Table 2 ). Only with the use of the combination of rifaximin and mesalazine, side effects were reported in 8.3% of patients. 21 
DISCUSSION
Several review articles focusing on the pathophysiology, clinical features, classification, drug therapies, and practice management of uncomplicated or complicated DD of the colon have been published to date. 6, [41] [42] [43] [44] [45] [46] [47] [48] In contrast to the most recent reviews and practice guidelines for the treatment of DD, we evaluated the quality of clinical studies and focused our attention on the efficacy of therapy on the symptoms and prevention of acute diverticulitis in relation to the clinical features of the patients. Despite the high prevalence and related high social and economic impact of symptomatic and/or complicated DD, the present review showed that only a limited number of prospective clinical trials on this condition have been performed. We identified and reviewed 31 prospective therapeutic clinical studies, the available data of which were inadequate for a meta-analysis because of the heterogeneity of the study design, patients' characteristics, type and regimens of therapy under study (combinations of drugs were evaluated in most trials), and outcome measures assessed. In fact, more than 2 treatment arms were considered in 7 studies, 11, 13, 15, 23, 24, 27, 32 and the efficacy of a combination of drugs or fiber was evaluated in 13 studies. 10,11,17,18,21,24 -26,29,31,32,37,38 Moreover, the same drug, at the same daily dose, showed different effects depending on the length of follow-up 20, 21, 23, 27 and on the scheduled regimen, whether it was continuous or administered at monthly cycles. 30 To date, only 6 randomized double-blind, placebocontrolled studies have been published in patients with symptomatic uncomplicated DD. These studies showed an overall benefit with the use of fiber supplementation and/or rifaximin in relieving some of the symptoms assessed, but only in one of these studies was the long-term follow-up adequate. 18 Four studies referred to a follow-up of between 2 weeks and 4 months. Considering that DD of the colon is a life-long condition, the outcome of therapy needs to be properly evaluated over a prolonged follow-up period.
As expected, high-quality, randomized controlled trials were not performed according to the most rigorous modern standards (ie, according to Consort statements). Only one randomized controlled trial provided adequate information and satisfied almost all the quality criteria proposed by Klein 7 and Spiller. 8 None of the studies provided adequate patient selection and definition. This is of the utmost importance if we consider the variability of the spectrum of patients that may be encountered in clinical practice. This is, in part, because a classification of DD of the colon has only recently been proposed, and the clinical hallmarks of diverticulitis such as prolonged (Ͼ24 h), presumed inflammatory, pain have recently been identified. 40 Another methodological issue emerging from the review is the limited use of a reproducible diagnostic tool for acute diverticulitis. In recent years, computed tomography has become the technique of choice to confirm diagnosis and assess the severity of acute diverticulitis. 49, 50 However, its use in selecting patients and in assessing outcome of ther-apies (ie, onset of acute diverticulitis) has not been consistently considered, so far.
Another point emerging from this review is the wide variability in the studies, in terms of patients included and outcome measures. The retrieved studies included 2 main subgroups of patients with uncomplicated DD of the colon: symptomatic patients and asymptomatic (previously symptomatic) patients, with or without previous attacks of acute diverticulitis. This affected the outcome of these studies and hampered comparison of the different therapies.
Symptomatic patients with uncomplicated DD, but with a poorly characterized history of acute diverticulitis, have been included in 17 studies, most of which compared fiber vs placebo with a short follow-up, and rifaximin plus fiber vs fiber alone. Overall, these studies suggest that fiber improves symptoms slightly more than placebo in the short term, and that their efficacy in maintaining prolonged remission of symptoms could be achieved with the use of rifaximin. Furthermore, only limited data suggest that continuous administration of mesalazine provides better results than pulsed rifaximin therapy.
A number of retrospective and epidemiological clinical studies, initially performed in the late 1970s, have demonstrated the beneficial effect of fiber on colonic function and its usefulness in preventing DD of the colon and its complications. 50 -61 On the basis of these observations, the use of fiber supplementation in DD has probably been widely adopted in clinical practice. However, this has been widely applied despite the absence of documented evidence of their effectiveness in well-designed, randomized clinical trials with consistent follow-up observations.
Rifaximin is a nonabsorbable antibiotic currently prescribed, in countries where it is available, for patients with bacterial bowel infections and traveler's diarrhea and for pre-and postoperative prophylaxis in gastrointestinal surgery. Indeed, a number of studies have also shown that rifaximin may be useful in irritable bowel syndrome (IBS) and in patients with small-bowel bacterial overgrowth, in particular, in reducing bloating, abdominal pain, flatulence, and loose or watery stools. [62] [63] [64] It should be considered that many symptoms reported by patients with IBS are the same as patients with DD of the colon, and that an increased odd for colonic diverticulosis in subjects with diarrhea-predominant IBS has recently been reported. 65 Therefore, it is possible that the studied populations included in this review may have selected patients with IBS. In this regard, the plausible mechanism of action of rifaximin in DD, although not fully investigated, could be its effect on gut bacteria and on gas-bloating symptoms and hydrogen excretion. 31 On the other hand, it has been also reported that a high prevalence of patients with DD, without a history of acute diverticulitis, have a resolution of symptoms with sigmoid resection, suggesting an alternative hypothesis about the origin of symptoms in DD. 66 Mesalazine is an anti-inflammatory drug widely used in inflammatory bowel diseases. Although not completely understood, the mechanism of action of mesalazine is based on the activation of nuclear receptors (ie, the ␥ form of peroxisome proliferator-activated receptors), which, in turn, downregulate inflammation and reduce inflammatory cytokine release. 67 In addition, recent preliminary data suggest that mesalazine may also act by reducing fecal bacteria populations by acting with an "antibiotic-like" action that may play a role in the beneficial effects observed in patients with DD. 68 Based on this evidence, mesalazine is expected to be more effective in patients with inflammation of the colon, and, therefore, those with previous acute diverticulitis.
As far as the prevention of acute diverticulitis is concerned, prevention is a matter of concern if we consider the striking clinical burden of this complication and its increasing prevalence at older ages. In fact, as the elderly population grows, a concomitant rise can be expected in the number of patients with DD and its complications. 48 There are still very few prospective studies aimed primarily at evaluating the efficacy of prophylactic therapy for acute diverticulitis. Only one randomized, placebocontrolled study failed to show any benefit of rifaximin over placebo, probably because of the enrollment of patients with a low risk of diverticulitis and the limited number of patients enrolled. 18 Indeed, pooling the available data from 4 large randomized trials, 17, [25] [26] [27] we observed that the association of rifaximin and fiber offers a significant benefit, in comparison with fiber supplementation alone, in preventing acute diverticulitis in patients with uncomplicated symptomatic DD. However, we also showed that a large number of patients have to be treated (57 patients) to prevent one attack of acute diverticulitis. This is probably due to the low risk of diverticulitis developing in this subgroup of patients. In fact, considering patients with recent attacks of acute diverticulitis, the yearly incidence of acute diverticulitis seems to be greater in this subgroup. 21 
CONCLUSION
Data emerging from this study suggest the potential usefulness of fiber, rifaximin, mesalazine, and probiotics, and their possible combination, in the treatment of uncomplicated symptomatic DD of the colon. However, we have found that reliable controlled therapeutic trials and solid scientific evidence to guide the treatment of this frequent and relevant disease in our clinical practice are still lacking. Therefore, this review of the literature mainly suggests the need of well-designed, placebo-controlled therapeutics trials that carefully take into consideration the clinical history of patients (ie, the number previous attacks of acute diverticulitis) to reliably identify those who should be treated and the therapeutic strategies that should be adopted.
